Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer

• मुख्य लेखकों: David E. Ybarra (लेखक), Maria Natalia Calienni (लेखक), Luis Felipe Barraza Ramirez (लेखक), E. Tais Aguayo Frias (लेखक), Cristian Lillo (लेखक), Silvia del Valle Alonso (लेखक), Jorge Montanari (लेखक), Fernando C. Alvira (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Elsevier, 2022-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Vismodegib (VDG) is an antineoplastic, a first-in-class Hedgehog signaling pathway inhibitor, indicated to treat locally advanced or metastatic basal cell carcinoma. Treatment with this drug was approved in 2012 by the US-FDA for oral administration (dose of 150 mg per day) in patients with a refusa...